01Purpose and principlesWhat the treatment does and how it fits into care.
CEA benefit after symptomatic carotid stenosis is strongly time dependent. A recently active plaque carries a high early recurrent embolic risk, and pooled trial evidence shows the greatest absolute benefit when surgery occurs within 14 days of the last retinal or cerebral event. The clock begins at symptom onset, not at clinic attendance, duplex confirmation or referral. Systems therefore need same-day communication, rapid corroborative imaging and parallel anaesthetic assessment.
Early does not mean unselected emergency surgery. A stable TIA with no infarct may permit very prompt CEA, while an acute stroke can carry infarct swelling and haemorrhagic transformation risk. ESVS recommends deferral when modified Rankin score is at least 3, infarction exceeds one third of the ipsilateral MCA territory, or consciousness is altered. Brain imaging, clinical trajectory and functional prognosis matter alongside stenosis severity.
Thrombolysis and mechanical thrombectomy add separate timing questions. Antithrombotics are withheld for 24 hours after intravenous thrombolysis, with repeat brain imaging before restarting, and ESVS advises considering delay of carotid intervention for six days. Tandem carotid disease treated during thrombectomy follows a hyperacute neurointerventional pathway and should not be reduced to the routine 14-day CEA algorithm.
Key points
- Treat any ongoing or recurrent focal deficit through the hyperacute stroke pathway first; carotid timing never supersedes brain imaging or reperfusion assessment.
- For a stable TIA or non-disabling stroke with indicated 50–99% NASCET stenosis, perform CEA as soon as safely feasible, preferably within 14 days of symptom onset.
- Defer CEA or CAS after disabling stroke, infarction exceeding one third of the ipsilateral MCA territory, altered consciousness or intracranial haemorrhage until neurological and imaging reassessment supports safety.
- Within the first 14 days, CEA is generally preferred over transfemoral carotid stenting because randomised evidence shows lower peri-procedural stroke or death.
- CEA within the first 48 hours remains a specialist case decision: uncomplicated TIA may differ from acute infarction, and haemorrhagic transformation risk must be weighed.
- After thrombolysis, antiplatelet and heparin treatment is withheld for 24 hours; ESVS advises considering a six-day delay before CEA or CAS.
- Do not delay urgent referral while optimising every comorbidity; investigate and treat surgical risk in parallel and document any reason for delay.
- Crescendo TIA or stroke in evolution can justify very urgent CEA in selected patients after multidisciplinary imaging review, rather than an automatic rule.
02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.
Neurologically stable TIA or non-disabling stroke, confirmed ipsilateral 50–99% NASCET stenosis, limited infarct and acceptable procedural risk support early CEA.
Dense persistent deficit with modified Rankin score at least 3 suggests lower immediate benefit and higher haemorrhagic risk.
Infarction exceeding one third of the ipsilateral MCA territory supports deferral until radiological and neurological improvement.
Repeated carotid-territory TIAs or stroke in evolution despite treatment require urgent multidisciplinary assessment for possible CEA within 24 hours.
Recent alteplase or tenecteplase exposure changes antithrombotic and procedural timing because intracranial and surgical bleeding risks rise.
Benefit declines with elapsed time, but a patient presenting after 14 days still needs expedited individual assessment rather than abandonment.
03Assessment before treatmentTests and checks that guide safe selection.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Urgent brain CT or MRIFirst step - Why
- Define infarct size, haemorrhage and evolving brain injury
- Interpretation and limitations
- Large territory infarction, oedema or blood favours deferral; small stable infarction supports early intervention when other criteria are met.
- 02
Duplex plus CTA or MRA - Why
- Confirm stenosis severity and procedural vascular anatomy
- Interpretation and limitations
- Use NASCET-equivalent grading and distinguish near-occlusion or occlusion; corroboration prevents an urgent operation based on a misleading single test.
- 03
Serial neurological examination - Why
- Document stability, disability and recurrent carotid symptoms
- Interpretation and limitations
- Stable minor deficit supports the standard early pathway, while deterioration or crescendo events require immediate specialist reconsideration.
- 04
Preoperative laboratory assessment - Why
- Identify anaemia, thrombocytopenia, renal dysfunction and metabolic hazards
- Interpretation and limitations
- Full blood count, coagulation, renal function and glucose guide perioperative safety without becoming reasons for avoidable open-ended delay.
- 05
Cardiac and anaesthetic assessment - Why
- Estimate myocardial and physiological procedural risk promptly
- Interpretation and limitations
- ECG and targeted cardiac work-up inform shared decisions; investigations should be proportionate and performed alongside carotid planning.
04Treatment approachPreparation, options, escalation and aftercare.
01ManagementStandard early CEA pathwayFirst stepRecent stable non-disabling carotid-territory event with indicated ipsilateral stenosis+
- 1Record the exact last-known symptom onset and neurological status, then refer urgently to a stroke-linked vascular service.
- 2Confirm 50–99% NASCET-equivalent stenosis with duplex plus CTA, MRA or second expert duplex and review current brain imaging.
- 3Complete MDT and anaesthetic assessment in parallel while best medical treatment continues and perioperative antithrombotics are coordinated locally.
- 4Perform CEA as soon as safely possible, preferably within 14 days, using an audited service with acceptable stroke and death outcomes.
- 5Repeat neurological assessment after surgery and control blood pressure closely to detect embolic stroke, thrombosis or hyperperfusion.
02SafetyDefer after major strokeMajor disability, large infarct, haemorrhage or altered consciousness makes early reperfusion hazardous+
- 1Continue acute stroke-unit care and secondary prevention appropriate to haemorrhage status, swallowing and independent embolic indications.
- 2Defer CEA and CAS rather than applying the stenosis threshold in isolation during unstable brain injury.
- 3Set a named review date with repeat neurological examination and brain imaging, assessing recovery, infarct evolution and life expectancy.
- 4Reconsider whether delayed intervention still offers net benefit; document medical management when disability or prognosis remains prohibitive.
03ExceptionVery urgent specialist decisionCrescendo TIA or stroke in evolution continues despite initial medical treatment+
- 1Reassess immediately for intracranial large-vessel occlusion, haemorrhage, free-floating thrombus and other causes needing different treatment.
- 2Bring stroke neurologist, vascular surgeon and neuroradiology expertise together without waiting for a routine MDT meeting.
- 3Consider CEA preferably within 24 hours only when imaging and clinical features suggest benefit exceeds perioperative haemorrhagic risk.
- 4If intervention is deferred, intensify monitored medical care and define the trigger and time for repeat review.
05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.
Aspirin
For suspected TIA give 300 mg orally once daily immediately unless contraindicated; after ischaemic stroke give 300 mg within 24 hours once haemorrhage is excluded, continuing to 14 days or earlier definitive antithrombotic review.Confirm swallowing route and review active bleeding, hypersensitivity, severe aspirin dyspepsia, anticoagulation, thrombocytopenia and reperfusion treatment. The operating team must specify perioperative continuation or substitution; do not create delay through an unowned antiplatelet plan.
Clopidogrel
Within 24 hours after an eligible minor ischaemic stroke (NIHSS ≤3) or moderate-to-high-risk TIA (ABCD2 ≥4), the selected UK product uses an oral clopidogrel loading dose of 300 mg, followed by 75 mg daily. Combine with aspirin 75–100 mg daily for 21 days before continuing single antiplatelet therapy. These product eligibility criteria never justify delaying suspected-TIA referral; a named specialist protocol must govern antiplatelets when CEA is contemplated.The selected SmPC does not recommend DAPT when CEA, thrombectomy, thrombolysis or anticoagulation is planned. Avoid in active bleeding or severe hepatic impairment; review other bleeding medicines and CYP2C19 inhibitors, especially omeprazole and esomeprazole.
06Complications, monitoring and follow-upAdverse effects, response and longer-term review.
- Track onset-to-referral, referral-to-imaging and onset-to-CEA intervals, with a documented reason for every delay beyond 14 days.
- Repeat the neurological examination whenever symptoms change and immediately before intervention; a new deficit returns the patient to acute stroke assessment.
- Review brain imaging after neurological deterioration or thrombolysis before restarting antithrombotics and before carotid intervention.
- Monitor perioperative blood pressure and headache, seizure or focal deficit because hyperperfusion and intracranial haemorrhage require urgent imaging.
- Audit 30-day stroke and death outcomes; the procedural risk must remain low enough for preventive benefit to be credible.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
Start the clock correctly
Use the most recent ipsilateral retinal or cerebral symptom onset. Starting from referral or scan date hides pathway delay and overstates timeliness.
Fourteen days is a ceiling
Preferably within 14 days means prompt safe surgery, not booking routinely on day 14. Earlier benefit is balanced against infarct and haemorrhagic risk.
Forty-eight hours is nuanced
CEA after uncomplicated TIA may be safer than after acute infarction. Very early surgery therefore requires brain imaging and an experienced joint team.
Thrombolysis changes the sequence
Withhold heparin and antiplatelets for 24 hours after intravenous thrombolysis, then restart after the required reassessment; consider a six-day procedural delay under ESVS guidance.
Deferral needs ownership
A safe decision to defer becomes unsafe if no repeat imaging, clinical review or final decision is scheduled. Name the clinician and date responsible.
08Common pitfallsFrequent interpretation and management errors.
- 01
Treating the 14-day target as permission to wait when safe surgery can be organised earlier.
- 02
Operating because stenosis is severe without checking disability, infarct volume, haemorrhage and consciousness.
- 03
Cancelling CEA indefinitely after major stroke without a dated neurological and imaging reassessment.
- 04
Restarting antiplatelet or heparin treatment immediately after thrombolysis instead of observing the 24-hour restriction.
- 05
Substituting carotid stenting for CEA solely to obtain a faster date during the first 14 days.
- 06
Delaying urgent referral until cardiac risk factors are perfectly investigated rather than running work-up in parallel.